Astrazeneca plc has added a novel target for heart failure to its discovery portfolio through its collaboration with Benevolentai Ltd.

A collaboration between Plaquetec Ltd. and a lab at the Babraham Institute has demonstrated the druggability of a pro-inflammatory protein discovered by Plaquetec.

Centogene NV and Evotec SE have announced the discovery of a new small molecule with potential to treat patients with type 2 and type 3 Gaucher disease, or neuronopathic Gaucher disease.

Fogpharma Inc. and Artbio Inc. have established a collaboration to co-develop a new class of α-radioligand therapeutics to maximize efficacy for patients with multiple types of cancer.

Neosphere Biotechnologies GmbH has entered into a collaboration with Kymera Therapeutics Inc. that seeks to unlock undrugged or poorly drugged disease-causing protein targets that can be addressed by targeted protein degradation.

Lantern Pharma Inc. has entered into a strategic artificial intelligence (AI)-driven collaboration with Oregon Therapeutics SAS to optimize the development of Oregon’s first-in-class protein disulfide isomerase (PDI) inhibitor drug candidate XCE-853 in novel and targeted cancer indications.

Cerevance Inc. has announced the achievement of the first milestone in its research collaboration with Merck & Co.

Repertoire Immune Medicines Inc. has entered a multiyear strategic collaboration with Bristol Myers Squibb Co. (BMS) to develop tolerizing vaccines for up to three autoimmune diseases.

Peptidream Inc. and Novartis Pharma AG have expanded their peptide-drug conjugate discovery collaboration announced in 2019, adding additional peptide radioligand therapies and other programs.

Alligator Bioscience AB reported that Orion Corp. has selected the lead bispecific antibodies from the companies’ second development program, and is exercising its option to develop these molecules under the existing 2021 research collaboration and license agreement.